Why Keytruda is essential for treating early-stage triple-negative breast cancer

Media coverage

• Title	Why Keytruda is essential for treating early-stage triple-negative breast cancer
  Media name/outlet	Korea Biomedical Review
  Date	7/05/24
  URL	ct.moreover.com/?a=53750981680&p=1gw&v=1&x=W-EbUxn1u6kjXSTwowAFMg
  Persons	Won Gu Lee

• Title	Hospital Why Keytruda is essential for treating early-stage triple-negative breast cancer It has been more than two years since MSD Korea's anti-PD-1 immuno-oncology drug Keytruda (pembrolizumab) won approval from the Ministry of Food and Drug Safety (MFD
  Media name/outlet	Korea Biomedical Review
  Date	7/05/24
  URL	ct.moreover.com/?a=53752165243&p=1gw&v=1&x=Y_i_rLk76QwqLSjYDV3p0g
  Persons	Won Gu Lee